iData Insights

Metastatic Melanoma - Pipeline Review, H2 2015 Now Available at iData Insights

News   •   Jan 30, 2016 11:51 IST

This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Metastatic Melanoma Overview 12

Therapeutics Development 13

Pipeline Products for Metastatic Melanoma - Overview 13

Pipeline Products for Metastatic Melanoma - Comparative Analysis 14

Metastatic Melanoma - Therapeutics under Development by Companies 15

Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 19

Metastatic Melanoma - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Metastatic Melanoma - Products under Development by Companies 24

Metastatic Melanoma - Products under Investigation by Universities/Institutes 29

Metastatic Melanoma - Companies Involved in Therapeutics Development 30

AB Science SA 30

AbbVie Inc. 31

Adaptimmune Limited 32

Affichem SA 33

Agalimmune Ltd 34

Agenus, Inc. 35

AGV Discovery, SAS 36

Altor BioScience Corporation 37

Amgen Inc. 38

Arisaph Pharmaceuticals, Inc. 39

Array BioPharma Inc. 40

Astex Pharmaceuticals, Inc. 41

AstraZeneca Plc 42

Basilea Pharmaceutica AG 43

Bioncotech Therapeutics S.L. 44

Bionomics Limited 45

Boehringer Ingelheim GmbH 46

Bristol-Myers Squibb Company 47

Caladrius Biosciences, Inc. 48

cCAM Biotherapeutics Ltd. 49

Cellceutix Corporation 50

Celldex Therapeutics, Inc. 51

Delcath Systems, Inc. 52

Digna Biotech, S.L. 53

DNA Therapeutics S.A. 54

Dynavax Technologies Corporation 55

Eisai Co., Ltd. 56

Eli Lilly and Company 57

Ensol Biosciences Inc. 58

F. Hoffmann-La Roche Ltd. 59

Galapagos NV 60

Galectin Therapeutics, Inc. 61

GlaxoSmithKline Plc 62

Idera Pharmaceuticals, Inc. 63

Immune Design Corp. 64

ImmuRx, Inc. 65

Incyte Corporation 66

IO Biotech ApS 67

Life Science Pharmaceuticals, Incorporated 68

Lipotek Pty Ltd. 69

Luitpold Pharmaceuticals, Inc. 70

MacroGenics, Inc. 71

MedImmune, LLC 72

Medivation, Inc. 73

MELEMA Pharma GmbH 74

Memgen, LLC. 75

Merck & Co., Inc. 76

Merck KGaA 77

Millennium Pharmaceuticals, Inc. 78

Morphotek, Inc. 79

NewLink Genetics Corporation 80

Novartis AG 81

Omeros Corporation 82

Oncolytics Biotech Inc. 83

OncoSec Medical Inc. 84

Ono Pharmaceutical Co., Ltd. 85

Pfizer Inc. 86

Pharmis Biofarmaceutica, Lda. 87

Philogen S.p.A. 88

Plexxikon Inc. 89

Polaris Pharmaceuticals, Inc. 90

Polyphor Ltd. 91

Prima BioMed Ltd. 92

Provectus Biopharmaceuticals, Inc. 93

Provenance Biopharmaceuticals Corp. 94

Reata Pharmaceuticals, Inc. 95

RXi Pharmaceuticals Corporation 96

Scancell Holdings Plc 97

Syndax Pharmaceuticals, Inc. 98

Takara Bio Inc. 99

TC BioPharm Limited 100

Tikcro Technologies, Ltd. 101

Ultimovacs AS 102

Metastatic Melanoma - Therapeutics Assessment 103

Assessment by Monotherapy Products 103

Assessment by Combination Products 104

Assessment by Target 105

Assessment by Mechanism of Action 114

Assessment by Route of Administration 120

Assessment by Molecule Type 122

Drug Profiles 124

(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 124

A-dmDT390-bisFv - Drug Profile 126

abemaciclib - Drug Profile 127

AF-122 - Drug Profile 129

AGI-134 - Drug Profile 130

ALT-801 - Drug Profile 131

ALT-803 - Drug Profile 134

AMG-232 - Drug Profile 136

Anti-CSPG4-IL2 - Drug Profile 137

Antibody to Inhibit HSP90 for Metastatic Melanoma - Drug Profile 138

ARI-4175 - Drug Profile 139

atezolizumab - Drug Profile 141

austrasulfone - Drug Profile 145

aviscumine - Drug Profile 146

BAL-3833 - Drug Profile 148

bevacizumab - Drug Profile 149

binimetinib + encorafenib - Drug Profile 155

BL-011256 - Drug Profile 157

BNC-420 - Drug Profile 158

BO-110 - Drug Profile 159

buparlisib hydrochloride - Drug Profile 160

cancer vaccine - Drug Profile 164

capmatinib - Drug Profile 165

CB-745 - Drug Profile 168

Cellular Immunotherapy 1 for Metastatic Melanoma - Drug Profile 169

Cellular Immunotherapy 2 for Metastatic Melanoma - Drug Profile 170

Cellular Immunotherapy 2 for Metastatic Melanoma - Drug Profile 171

Cellular Immunotherapy for Cancer and Viral Infections - Drug Profile 172

Cellular Immunotherapy for Metastatic Melanoma - Drug Profile 174

Cellular Immunotherapy for Metastatic Melanoma - Drug Profile 175

Cellular Immunotherapy to Target HERV-K for Metastatic Melanoma - Drug Profile 177

Cellular Immunotherapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma - Drug Profile 178

Cellular Immunotherapy to Target MART-1 and MELOE-1 for Metastatic Melanoma - Drug Profile 179

Cellular Immunotherapy to Target MART-1 for Metastatic Melanoma - Drug Profile 180

Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanoma - Drug Profile 181

Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile 182

Charis-1000 - Drug Profile 183

CM-24 - Drug Profile 184

dabrafenib mesylate - Drug Profile 185

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 188

Darleukin - Drug Profile 189

DB-039 - Drug Profile 191

diphencyprone - Drug Profile 192

DNA IL-12 - Drug Profile 193

Drugs to Antagonize ETBR for Metastatic Melanoma - Drug Profile 196

DT-01 - Drug Profile 197

E-6201 - Drug Profile 199

ecromeximab - Drug Profile 201

eltrapuldencel-T - Drug Profile 202

encorafenib - Drug Profile 205

enoblituzumab - Drug Profile 207

entinostat - Drug Profile 209

epacadostat - Drug Profile 213

FC-311 - Drug Profile 215

G-305 - Drug Profile 216

glembatumumab vedotin - Drug Profile 218

GLPG-1790 - Drug Profile 220

GRMD-02 - Drug Profile 221

GSK-2241658A - Drug Profile 224

GSK-2302025A - Drug Profile 225

GSK-3377794 - Drug Profile 226

guadecitabine - Drug Profile 228

HF-10 - Drug Profile 232

ICOVIR-5 - Drug Profile 234

IMO-2125 - Drug Profile 235

IMP-321 - Drug Profile 237

indoximod - Drug Profile 239

IO-102 - Drug Profile 241

ISF-35 - Drug Profile 242

KM-3174 - Drug Profile 244

lenvatinib - Drug Profile 248

lirilumab - Drug Profile 254

LN-144 - Drug Profile 256

LOC-paclitaxel - Drug Profile 259

LV-305 - Drug Profile 260

LY-3009120 - Drug Profile 261

M-200 - Drug Profile 262

masitinib - Drug Profile 263

MEDI-3617 - Drug Profile 269

melphalan - Drug Profile 270

miRNA-7-5p - Drug Profile 273

MK-0429 - Drug Profile 274

Monoclonal Antibodies to Antagonise PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 275

Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma - Drug Profile 276

Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma - Drug Profile 277

MORAb-050 - Drug Profile 278

navitoclax dihydrochloride - Drug Profile 279

nilotinib - Drug Profile 281

nintedanib - Drug Profile 285

nivolumab - Drug Profile 290

omaveloxolone - Drug Profile 298

onalespib - Drug Profile 301

ontuxizumab - Drug Profile 304

palbociclib - Drug Profile 306

panobinostat - Drug Profile 310

pasireotide - Drug Profile 316

PDC-mel - Drug Profile 319

pegargiminase - Drug Profile 320

pelareorep - Drug Profile 324

pembrolizumab - Drug Profile 329

pexidartinib - Drug Profile 338

pidilizumab - Drug Profile 340

pimasertib hydrochloride - Drug Profile 342

POL-7085 - Drug Profile 345

PV-10 - Drug Profile 346

Q-122 - Drug Profile 350

Q-204 - Drug Profile 352

RAF-265 - Drug Profile 353

Recombinant Protein for Metastatic Melanoma - Drug Profile 354

Recombinant Protein for Oncology - Drug Profile 355

ribociclib - Drug Profile 356

SCIB-1 - Drug Profile 359

SD-101 - Drug Profile 362

Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer - Drug Profile 364

Small Molecules to Antagonize ET-B for Oncology - Drug Profile 365

Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 366

Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Cancer - Drug Profile 367

SRX-1177 - Drug Profile 368

sunitinib malate - Drug Profile 369

TAK-580 - Drug Profile 373

talimogene laherparepvec - Drug Profile 375

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.


iData Insights

Tel: 1-866-237-2965



About iData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.